QiShen YiQi and its components attenuate acute thromboembolic stroke and carotid thrombosis by inhibition of CD62P/PSGL-1-mediated platelet-leukocyte aggregate formation

• Published in: Biomedicine & pharmacotherapy Vol. 160; p. 114323
• Main Authors: Yu, Mingxing, Xiao, Guangxu, Han, Linhong, Peng, Li, Wang, Huanyi, He, Shuang, Lyu, Ming, Zhu, Yan
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-04-2023; Elsevier
• Subjects: Animals; Carotid artery thrombosis; Carotid Artery Thrombosis - drug therapy; Carotid Artery Thrombosis - metabolism; Component-based Chinese medicine; Leukocytes - metabolism; Mice; P-Selectin - metabolism; Platelet-leukocyte aggregate; Polyesters; QiShen YiQi; Rats; Stroke - complications; Stroke - drug therapy; Stroke - metabolism; Thromboembolic stroke; Thrombosis - drug therapy; Thrombosis - metabolism; Thromboembolic stroke; PLA; MAC-1; Carotid artery thrombosis; GPⅠbα; QiShen YiQi; HX; YQ; Platelet-leukocyte aggregate; PSGL-1; CD62P; QSYQ; TCM; Component-based Chinese medicine
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.114323

QiShen YiQi (QSYQ) dropping pill, a component-based Chinese medicine consisting of benefiting Qi (YQ) and activating blood (HX) components, has been reported to exert a beneficial effect on cerebral ischemia-induced stroke. However, its efficacy and pharmacological mechanism on acute thromboembolic stroke is not clear.
This study is to explore the preventative effect and pharmacological mechanism of QSYQ and its YQ/HX components on the formation of platelet-leukocyte aggregation (PLA) in acute thromboembolic stroke.
In vivo thromboembolic stroke model and FeCl3-induced carotid arterial occlusion models were used. Immunohistochemistry, Western blot, RT-qPCR, and flow cytometry experiments were performed to reveal the pharmacological mechanisms of QSYQ and its YQ/HX components.
In thromboembolic stroke rats, QSYQ significantly attenuated infarct area, improved neurological recovery, reduced PLA formation, and inhibited P-selection (CD62P)/ P-selectin glycoprotein ligand-1 (PSGL-1) expressions. The YQ component preferentially down-regulated PSGL-1 expression in leukocyte, while the HX component preferentially down-regulated CD62P expression in platelet. In carotid arterial thrombosis mice, QSYQ and its YQ/HX components inhibited thrombus formation, prolonged vessel occlusion time, reduced circulating leukocytes and P-selectin expression. PLA formation and platelet/leukocyte adhesion to endothelial cell were also inhibited by QSYQ and its YQ/HX components in vitro.
QSYQ and YQ/HX components attenuated thromboembolic stroke and carotid thrombosis by decreasing PLA formation via inhibiting CD62P/PSGL-1 expressions. This study shed a new light on the prevention of thromboembolic stroke.
[Display omitted]
•QiShen YiQi and its Qi-benefiting/blood-activating components attenuated acute thromboembolic stroke and carotid thrombosis.•QSYQ inhibits platelet-leukocyte aggregate formation and platelet/leukocyte adhesion to endothelial cell.•QSYQ inhibits platelet/leukocyte adhesion molecule CD62P/PSGL-1 expressions.•Qi-benefiting and blood-activating components of QSYQ act synergistically to exert the anti-thrombotic effect.